Showing 1551-1560 of 2656 results for "".
- FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/fda-accepts-genentechs-biologics-license-application-for-satralizumab-for-neuromyelitis-optica-spectrum-disorder/2477055/Genentech announced the FDA has accepted the company’s biologics license application (BLA) for satralizumab for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The European Medicines Agency (EMA) has also validated the company’s Marketing Authorization
- Bausch Health Licenses Clearside Biomedical’s Xipere, An Investigational Treatment For Macular Edema Associated With Uveitishttps://modernod.com/news/bausch-health-licenses-clearside-biomedicals-xipere-an-investigational-treatment-for-macular-edema-associated-with-uveitis/2477035/Bausch Health Companies announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the United States and
- Envision Dallas Lighthouse for the Blind to House American Foundation for the Blind Center on Vision Loss, Esther’s Placehttps://modernod.com/news/envision-dallas-lighthouse-for-the-blind-to-house-american-foundation-for-the-blind-center-on-vision-loss-esthers-place/2477004/Envision announced a collaboration with American Foundation for the Blind (AFB) to establish Envision Dallas Lighthouse for the Blind as the new home of the American Foundation for the Blind Center on Vision Loss and Esther’s Place. A grand opening is expected in spring 2020. Envision Dallas Ligh
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Roche’s Purchase of Spark Therapeutics Faces Further Delay Amid Scrutiny From US, UK Regulatorshttps://modernod.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/The US Federal Trade Commission requested additional information and documentary material from Roche and Spark Therapeutics in connection with its review of the companies’ pending deal, the drugmakers reported Monday. Roche noted that as a result, its $4.3-billion offer to acquire Spark has
- FDA Approves Bausch + Lomb’s Lotemax SM For The Treatment Of Postoperative Inflammation And Painhttps://modernod.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/Bausch + Lomb announced that the FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel 0.5%, Lotemax SM delivers a submicron particle size for faste
- Ophtec’s Preloaded Capsular Tension Ring Ringject Receives Approval in Chinahttps://modernod.com/news/ophtecs-preloaded-capsular-tension-ring-ringject-receive-approval-in-china/2476275/Ophtec was granted CFDA approval for the preloaded capsular tension ring (CTR) Ringject in China. Ringject is a preloaded, single use capsular tension ring designed to be self-loading for surgical convenience. CTRs were originally introduced to strengthen the zonule in eyes with zonular de
- AbbVie’s Humira (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Noninfectious Anterior Uveitishttps://modernod.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/AbbVie announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic noninfectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropr
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- GenSight’s Gene Therapy GS010 Fails Second Late-Stage Leber Hereditary Optic Neuropathy Studyhttps://modernod.com/news/gensights-gene-therapy-gs010-fails-second-late-stage-leber-hereditary-optic-neuropathy-study/2476321/GenSight Biologics announced that a phase 3 study investigating a single injection of the experimental gene therapy GS010 failed to improve vision loss compared to sham treatment in patients with 11778-ND4 Leber hereditary optic neuropathy (LHON). In the RESCUE study, patients with